Analyst Craig Bijou of Bank of America Securities reiterated a Sell rating on Integra Lifesciences (IART ... intracranial monitoring equipment, and cranial stabilization equipment; and precision ...

One company to watch right now is Integra LifeSciences (IART). IART is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Value investors also frequently use the P/S ratio.

In a regulatory filing on Monday, Integra LifeSciences (IART) said that on December 19, 2024, a subsidiary received a warning letter from the U.S. FDA. The warning letter relates to quality system ...

Integra Lifesciences recently received an FDA warning letter pertaining to quality systems issues at several facilities. The company announced in an SEC filing that it received the warning letter ...

Invesco Small Cap Value Fund highlighted stocks like Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the third quarter 2024 investor letter. Integra LifeSciences Holdings Corporation ...

Clearly, options traders are pricing in a big move for Integra LifeSciences shares, but what is the fundamental picture for the company? Currently, Integra LifeSciences is a Zacks Rank #2 (Buy ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Integra LifeSciences Holdings Corp (NASDAQ:IART), a medical device company with a market capitalization of $1.79 billion, disclosed Monday that it received a warning letter from the U.S. Food and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...